Suppr超能文献

贲门失弛缓症:最佳治疗方法是什么?

Achalasia: what is the best treatment?

作者信息

Ahmed Adamu

机构信息

Division of General Surgery, Department of Surgery, Ahmadu Bello University Teaching Hospital, Zaria, Nigeria.

出版信息

Ann Afr Med. 2008 Sep;7(3):141-8. doi: 10.4103/1596-3519.55662.

Abstract

BACKGROUND

Achalasia is an infrequent primary motility disorder of the esophagus. Because of uncertain etiology, treatment is only palliative and is directed at decreasing lower esophageal sphincter pressure, improving esophageal emptying and relieving the symptoms of achalasia. Current treatment options include pharmacological, endoscopic and surgical. We undertook a systematic literature review of the management strategies currently available for achalasia.

METHOD

A Medline, PubMed and Cochrane database search was conducted using reference manager 11. Original articles and reviews published in the English literature on the management of achalasia were reviewed. Emphasis was placed on articles published in the last ten years on randomized controlled trials comparing the various forms of treatment.

RESULTS

Esophageal manometry is the standard diagnostic evaluation for achalasia. Accurate diagnosis can also be made based on clinical findings and barium esophagogram. Medical treatment with nitrates or calcium channel blockers has variable results in alleviating the symptoms of achalasia but long-term results are disappointing because of tolerance and side effects. Intrasphincteric injection of botulinum toxin, pneumatic dilatation and surgical myotomy are variably effective at controlling the symptoms of achalasia but each modality has specific strength and weaknesses which make their choice suitable in a particular group of patients. While pneumatic dilatation is superior to botulinum toxin injection surgical myotomy provides the best long-term control of symptoms in patients with achalasia.

CONCLUSION

Laparoscopic myotomy should be the initial treatment for most patients with achalasia. Pneumatic dilatation is the most cost-effective alternative but its long-term efficacy is less than that of surgical myotomy. Endoscopic botulinum toxin injection can be considered when other forms of treatment are contraindicated.

摘要

背景

贲门失弛缓症是一种罕见的食管原发性动力障碍性疾病。由于病因不明,治疗仅为姑息性,旨在降低食管下括约肌压力、改善食管排空并缓解贲门失弛缓症的症状。目前的治疗选择包括药物治疗、内镜治疗和手术治疗。我们对目前可用于贲门失弛缓症的管理策略进行了系统的文献综述。

方法

使用文献管理软件Reference Manager 11对Medline、PubMed和Cochrane数据库进行检索。对英文文献中发表的关于贲门失弛缓症管理的原创文章和综述进行了回顾。重点关注过去十年发表的比较各种治疗形式的随机对照试验文章。

结果

食管测压是贲门失弛缓症的标准诊断评估方法。根据临床表现和食管钡餐造影也可做出准确诊断。使用硝酸盐或钙通道阻滞剂进行药物治疗在缓解贲门失弛缓症症状方面效果不一,但由于耐受性和副作用,长期效果令人失望。括约肌内注射肉毒杆菌毒素、气囊扩张和手术肌切开术在控制贲门失弛缓症症状方面效果各异,但每种方法都有其特定的优缺点,这使得它们在特定患者群体中的选择更为合适。虽然气囊扩张优于肉毒杆菌毒素注射,但手术肌切开术为贲门失弛缓症患者提供了最佳的症状长期控制效果。

结论

腹腔镜肌切开术应作为大多数贲门失弛缓症患者的初始治疗方法。气囊扩张是最具成本效益的替代方法,但其长期疗效低于手术肌切开术。当其他治疗形式禁忌时,可考虑内镜下肉毒杆菌毒素注射。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验